Introduction
The advent of beta-receptor blocking agents in the management of angina pectoris has been a major advance in a field where previously the profusion of long-acting coronary vasodilators used was a testimony to their ineffectiveness. Pronethalol was the first successful drug in the treatment of angina (Dornhorst and Robinson, 1962 ; Alleyne et al., 1963) , and was soon superseded by propranolol, which has a therapeutic potency tenfold that of pronethalol and is free of the untoward sideeffects of that compound (Black et al., 1964) . More recently a newer compound has been produced, verapamil (Cordilox, iproveratril, Isoptin) , which on the basis of experimental work by Hass (1964) was introduced as a new beta-receptor blocking agent, and it was claimed that, unlike propranolol, yerapamil does not induce either coronary artery vasoconstriction or bronchoconstriction (Haas, 1964) . These experimental results have, however, been challenged (Fitzgerald and Barrett, 1967;  Wilkinson, 1967; Grant et al., 1968) , and in the present state of knowledge it cannot be convincingly maintained that verapamil is indeed a beta-receptor blocking agent.
However, some preliminary clinical studies of the use of verapamil in angina have shown its efficacy (Hoffmann, 1964; Fischer, 1965 ; Hofbauer, 1966) but these have been uncontrolled and assessment has been largely subjective, though another study by Wette et al. (1966) has shown improvement in the ischaemic patterns in the electrocardiogram after longterm treatment with verapamil. Provided verapamil has no deleterious effects on the heart or other organs then the exact mechanism of action in angina, whether this involves betareceptor blockade or direct depression of myocardial contractility, is of less importance than whether the drug is an effective agent in angina pectoris. It was with these considerations in mind that it was decided to undertake a controlled double- All patients attended the clinic monthly and the study began with a control period of one month, when the only drug taken for angina was trinitrin. During the next four months of the trial the patients were given individual monthly supplies of identical tablets in random order comprising verapamil 40 mg., verapamil 120 mg., propranolol 100 mg., or a placebo, the tablets to be taken three times daily. Neither the patient nor the observer knew which drug had been given. In addition each patient was supplied with a specific number of trinitrin tablets at each visit to be used freely for their anginal attacks; they were also given a record card and were asked to fill it in each day, stating only the number of attacks they had had that day. At each monthly visit this card was collected and a new one issued and the remaining trinitrin tablets were counted, giving a more objective assessment of the number of attacks. To eliminate any errors from a carry-over effect of the previous month's therapy only the last two weeks of the four-week period was used in obtaining the incidence of anginal attacks and the number of trinitrin tablets consumed. Any sideeffects during the previous month were also noted.
Exercise tolerance tests were carried out at the beginning of the study and at subsequent monthly visits. The test used was a modification of Master's two-step test and has been described in detail previously (Sandler, 1961) . In addition to conventional electrocardiography recording chest lead V5 before and after exercise, the patient was monitored continuously during exercise by radiocardiography, which is more sensitive in revealing ischaemic change and also safer by ensuring that ischaemic change can be detected immediately, especially if unaccompanied by angina, allowing the exercise to be terminated immediately (Sandler, 1967 (Lloyd-Thomas, 1961 ; Master and Rosenfeld, 1961 ; Bellet et al., 1962) ; junctional depression was accepted as significant only when the QX/QT ratio exceeded 50% (Master and Rosenfeld, 1961 ). The indices of assessment which were recorded during the exercise test were the number of circuits accomplished by the patient and the exercise time before angina and/or ischaemic change developed in the electrocardiogram, the duration of angina, the degree and duration of S-T depression either in the radiocardiogram or in lead V5, and the heart rate before and during exercise. In addition the resting blood pressure was measured in the lying and standing positions before each exercise test was begun, to determine whether any of the preparations taken during the previous month had exerted a hypotensive effect.
The nature and purpose of the investigation was made clear to all the patients.
Results Table I shows the weekly incidence of angina recorded by the patient and the number of trinitrin tablets used during the control period and with each of the four preparations studied. In this and the subsequent tables, in addition to calculating mean values for the whole group, the differences in individual patients resulting from the various preparations compared with the control period have been analysed statistically, so that variation between different subjects could be eliminated and any changes produced by the drugs could become more apparent. The significance of differences (P values) are shown in all the tables. Compared with the control period there was a significant reduction in the actual number of anginal attacks and a significant change in the incidence of attacks recorded by the patients after treatment with propranolol and high and low doses of verapamil, though there were no significant differences between the three preparations themselves. When trinitrin consumption is considered (Table I) Table III , which shows the degree and duration of ischaemic S-T depression in both the radiocardiogram and lead V5. In the radiocardiogram both verapamil 120 mg. t.d.s. and propranolol produced a favourable and significant mean change in the amount of S-T depression developing during exercise, but only propranolol significantly altered the duration of the S-T depression on the radiocardiogram. It is of interest that there was a significant change in the duration of S-T depression following use of the placebo. In conventional lead V5 both verapamil 120 mg. t.d.s. and propranolol were associated with a favourable and significant effect on the mean change in duration of S-T depression after termination of exercise, and this finding was highly significant with verapamil (P<0.0005). Table IV shows the changes in heart rate during exercise with the four preparations. Compared with the control period the heart rate before exercise was significantly lower after 
Discussion
The value of sympathetic beta-receptor blocking agents in the treatment of angina has already been well established (Gillam and Pritchard, 1965 ; Birkett and Chamberlain, 1966; Grant et al., 1966) . The present study confirms objectively the improvement in myocardial ischaemia occurring during exercise in anginal patients taking propranolol 300 mg. orally daily. However, as a result of the intensive beta-adrenergic blockade produced by propranolol unwelcome side-effects may occur such as bronchoconstriction and deterioration in existing heart failure, and sometimes coronary artery vasoconstriction may develop (Wolfson et al., 1966) . Verapamil was introduced as a new mild beta-blocking agent which had a direct vasodilating action on the coronary circulation (Melville et al., 1964; Luetsai at., 1966) and which did not produce any bronchoconstriction.
Experimental evidence showed that verapamil can antagonize the effects of isoprenaline in isolated heart preparations and in annesthetized animals (Haas, 1964; Schmid and Hanna, 1967) , but it has been pointed out that, unlike with the use of propranolol, this occurs only with doses high enough to produce myocardial depression (Melville et al., 1964 ; Melville and BlCnfey, 1965; Shanks, 1967) . Furthermore, it has been shown that the abolition of exercise tachycardia, which is an important effect of a true beta-blocker, does not occur when verapamil was given to healthy volunteers (Fitzgerald and Barrett, 1967) , but Bateman (1967) pointed out that reduction of exercise tachvcardia has been shown in anginal patients (Atterhog and Porid, 1966) . In the present study, however, verapamil did not slow the heart rate during exercise, though propranolol clearly did produce this effect.
BA MEDICAL Joutnnr
The coronary vasodilator action of verapamil has been shown experimentally (Schlepper and Witzleb, 1962; Haas, 1964; Schmahl and Betz, 1964) and has been confirmed in normal human subjects (Knoch et al., 1963 ; Luebs et al., 1966) , but Mignault (1966) was unable to find any angiocardiographic evidence of coronary vasodilatation in anginal subjects after intravenous verapamil. There have been several favourable reports on the use of verapamil in angina pectoris, but they have been largely uncontrolled and subjectively assessed, results being based on improvement on incidence of angina (Hoffmann, 1964; Fischer, 1965; Hofbauer, 1966; Mignault, 1966) . The suggestibility of anginal patients with any new preparation has been well established (Greiner et al., 1950) and the favourable response to placebos clearly shown (Cole et al., 1968) , so that the necessity for a double-blind trial becomes apparent. Neumann and Luisada (1966) did find significant improvement in the incidence of angina with verapamil in a double-blind trial in 30 geriatric patients, but assessment was again wholly subjective and therefore of limited value in view of the lack of direct relationship between the development and severity of angina and the degree of actual coronary insufficiency (Russek et al., 1955 ).
The present study shows clearly that verapamil in a dose of 120 mg. three times daily significantly reduces the incidence of angina and the weekly consumption of trinitrin and also leads to a significant increase in the amount of exercise possible before the development of angina. Gillam, 1964) or to a chronic reduction in cardiac output (Frohlich et al., 1968) . The mode of action of propranolol in angina probably involves several different mechanisms (Frieden, 1967) , including prevention by beta-receptor blockade of the myocardial oxygen-wasting effects of catecholamines liberated by exertion or emotion, suppression of myocardial contractility by a quinidine-like action, topical anaesthesia, and reduction of cardiac work by the hypotensive action of the drug. In the absence of satisfactory evidence that therapeutic dose levels of verapamil produce beta-receptor blockade and the lack of consistent evidence that the drug produces coronary vasodilatation in anginal subjects, its undoubtedly beneficial effects in angina are probably attributable to a direct suppression of myocardial contractility by the quinidine-like effect of the drug shown by Melville et al. (1964) .
We are indebted to Mr. B. Bamford and Miss V. Clarke for technical assistance with the electrocardiography. We would also like to thank Dr. F. J. A. Bateman, of Pfizer Ltd., for the supply of all the drug preparations used in this trial.
INTRODUCTION
Rubidomycin is the first antibiotic to show therapeutic effect in acute leukaemia in man. It was discovered in France and shortly afterwards independently in Italy, where it was called daunomycin. It has been shown to be effective when used in acute leukaemia in children and adults (Bernard et al., 1967) or when given in combination with other chemotherapeutic agents in acute lymphoblastic leukaemia (Mathe et al., 1967) . The incidence of remission in patients with myeloblastic leukaemia has been higher than that recorded for any other form of therapy (Dreyfus et al., 1968) . This study has beaten concerned mainly with the use of rubidomycin in the particularly intractable group of adult acute myeloblastic leukaemia. It has also been used to treat a few patients with acute lymphoblastic leukaemia who have relapsed after conventional therapy. D PATIENTS TREATED AND METHOD OF ADMINISTRATION Twenty-two adults with leukaemia have been treated with rubidomycin between November 1966 and June 1968. Sixteen adults between the ages of 17 and 81 with acute myeloblastic leukaemia received treatment. Eight of these had had some form of chemotherapy but were not in remission, while the other eight had received only blood transfusions or antibiotics. The three patients with acute lymphoblastic leukaemia had all had at least four chemotherapeutic agents. One of them had not achieved remission, while the other two had had two and four remissions respectively.
Rubidomycin hydrochloride is supplied as a microcrystalline orange-red powder readily soluble in water. About 2 ml. of sterile normal saline is required to dissolve the contents of one ampoule. The total volume injected is some 15 to 20 ml. It was administered by injection into the tubing of a fast-flowing intravenous saline infusion. Great care was taken to avoid extravasation of the material, which was intensely painful even in small amounts and might cause necrosis. The rate of infusion was increased after the injection to prevent stasis.
Two schedules of administration were employed during the study. The first was to give 2 mg./kg. body weight daily to a maximum of 10 mg./kg. unless signs of toxicity supervened. About half the patients were treated in this way. The second method' was to give an initial dose of 2 mg./kg./day, then
